NOKIA:OMXHEXNokia Oyj Analysis
Data as of 2026-05-20 - not real-time
€11.98
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Technical indicators show a bullish momentum with the 20‑day SMA (≈10.6) comfortably above the 50‑day (≈8.7) and 200‑day (≈5.95) averages, and a MACD line just above its signal, confirming the bullish bias. However, the RSI is perched at around 71, signaling an overbought condition, while trading volume has been trending down, suggesting waning participation as the price hovers near the resistance level of €12.40.
Fundamental valuation is starkly misaligned: a trailing P/E of roughly 85 versus an industry average of 38, and a discounted cash‑flow fair value of only €4.56, implying a downside of over 22% from the current €11.98 price. The dividend yield of 1.21% is backed by a 100% payout ratio, raising concerns about sustainability given modest ROE (~3.7%) and low revenue growth (≈2.4%).
Risk profile combines high 30‑day volatility (~60%) with a low beta (~0.41), indicating that while the stock is less correlated with the broader market, its price swings are pronounced. Sector and regulatory risks are medium, geographic exposure is diversified, and liquidity risk is medium due to recent volume contraction. Overall, the stock appears significantly overvalued with limited upside, warranting caution.
Fundamental valuation is starkly misaligned: a trailing P/E of roughly 85 versus an industry average of 38, and a discounted cash‑flow fair value of only €4.56, implying a downside of over 22% from the current €11.98 price. The dividend yield of 1.21% is backed by a 100% payout ratio, raising concerns about sustainability given modest ROE (~3.7%) and low revenue growth (≈2.4%).
Risk profile combines high 30‑day volatility (~60%) with a low beta (~0.41), indicating that while the stock is less correlated with the broader market, its price swings are pronounced. Sector and regulatory risks are medium, geographic exposure is diversified, and liquidity risk is medium due to recent volume contraction. Overall, the stock appears significantly overvalued with limited upside, warranting caution.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- RSI indicates overbought conditions
- Price nearing resistance at €12.40
- Decreasing trading volume
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD and SMA alignment
- Support level at €8.37 providing downside cushion
- High valuation metrics still out of line with fundamentals
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- DCF fair value far below market price
- Unsustainable dividend payout ratio
- Modest revenue growth and low profitability margins
Key Metrics & Analysis
Financial Health
Revenue Growth2.40%
Profit Margin3.98%
P/E Ratio85.5
ROE3.72%
ROA2.76%
Debt/Equity15.63
P/B Ratio3.2
Op. Cash Flow€2.0B
Free Cash Flow€1.6B
Industry P/E38.0
Technical Analysis
TrendBullish
RSI71.0
Support€8.37
Resistance€12.40
MA 20€10.61
MA 50€8.74
MA 200€5.95
MACDBullish
VolumeDecreasing
Fear & Greed Index89.27
Valuation
Fair Value€4.56
Target Price€9.24
Upside/Downside-22.85%
GradeOvervalued
TypeValue
Dividend Yield1.21%
Risk Assessment
Beta0.41
Volatility59.88%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.